Pyridinium compounds useful for the treatment of AGE-related diseases

Abstract: The invention discloses novel compounds of the pyridinium series useful for the management of diabetes and aging-related vascular complications, including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological disorders and discoloration of teeth, by breaking preformed AGE, or pharmaceutically acceptable salts thereof. The invention also discloses, method for preparation of the novel compounds of the series and pharmaceutical composition comprising one or more of these compounds. The invention further discloses a method of treatment of a diabetic patient by administering the compounds either singly or in combination with drugs for antidiabetic therapy.

Description: The present, invention relates to a pyridinium derivative according to claim 1, a process for the preparation of pyridinium salt derivatives according to claim 2, the use of a compound according toclaims 3, 10 and 11, a pharmaceutical composition according to claim 4, a method for the preparation of a parenteral formulation according to claim 8. The present invention relates to a new class of compounds of pyridinium series and to their use in treatment of diabetes and related illnesses. More particularly the invention relates to compounds of this series, methods for their preparation, pharmaceutical composition containing these compounds and their use in the treatment of complications of diabetes mellitus. The compounds of this series exhibit AGE breaking activity, which is essential for the treatment of diabetic and aging-related complications including kidney disease, nerve damage, atherosclerosis, retinopathy and dermatological conditions. The invention also extends to the method of reversing the discoloration of teeth resulting from nonenzymatic browning in the oral cavity which comprises administration of an amount effective to reverse pre-formed advanced glycosylation crosslinks. Maillard in 1912 found that reducing sugars, such as glucose and ribose react with proteins to form brown pigments. Further studies have shown that this is an irreversible non-enzymatic reaction, which occurs in several natural systems including stored foodstuff. Maillard reaction occurs in two stages, early and advanced. Initially, proteins react with glucose to form stable Amadori products, which subsequently crosslinks to form advanced glycation end products (AGE). In most cases, the formation of AGE also accompanies browning of the proteins and increase in the fluorescence. In diabetes, where blood glucose level is significantly higher than normal, the reaction of glucose with several proteins such as haemoglobin, lens crystallin and collagen, gives rise to the formation of AGE, which in turn, is responsible for the complications associated with diabetes, such as nephropathy, microangiopathy, endothelial dysfunction and other organ dysfunctions. In addition, the activity of several growth factors, such as basic fibroblast growth factor, is also impaired. AGE products, unlike normal proteins in tissue, have a slower rate of turnover and replenishment. It has been reported that AGE products may in fact elicit a complex immunological reaction involving RAGE (Receptor for Advanced Glycation End Products) receptors and activation of several incompletely defined immunological processes. It has been documented that diabetes with evidence of microangiopathy and macroangiopathy also show evidence of oxidative stress, the mechanism of which has not been elucidated. In vitro AGE formation can be studied in the laboratory by incubating reducing sugars, such as ribose or glucose with bovine serum albumin. AGE formation can be detected by increase in the fluorescence or increased cross reactivity with anti-AGE antibodies. The increase in fluorescence seems to precede formation of AGE specific antigenic epitopes. This increase in fluorescence is used to monitor the increased AGE formation in vitro (Brownlee M et al, Science 1986; 232:1629-1632). In addition to the increase in the fluorescence, one of the most important features of in vitro AGE formation is the formation of antigenic epitopes that are specific to AGE and not to the native proteins. Therefore, it is possible to raise antibodies against advanced glycation end products of one protein and use them to detect AGE formation in other proteins. This has served as an important analytical tool in AGE research. Due to the clinical significance of AGE formation, many approaches are being used to diagnose, prevent, or revert AGE formation in the body. The formation of AGE could be inhibited by reacting with an early glycosylation product that results from the original reaction between the target protein and glucose. The inhibition was believed to take place as the reaction between the iahibitor and the early glycosylation product appeared to interrupt the subsequent reaction of the glycosylated protein with additional protein material to form the cross linked late stage product. Compounds like aminoguanidine act to inhibit AGE formation by such mechanism. The formation of AGE on long-lived proteins is also associated with cross-linking of these proteins. The AGE derived protein crosslinks have been shown to be cleaved by compounds like N- phenacyl thiazolium bromide (PTB), which reacts with and cleaves covalent, AGE derived protein cross links (Vasan et al. Nature 1996; 382: 275-278 ; US 5,853,703, Date of Patent : Dec. 29, 1998). The mechanism of reducing the AGE content in tissues is expected to take place relatively rapidly, in contrast to aminoguanidine, which acts slowly by its very nature of mechanism of action. This current specification is related to compounds of pyridinium class, which break pre-formed AGE, like PTB, and in some cases even more effectively than PTB. The pyridinium derivative is defined in claim 1, the process for the preparation of pyridinium salt derivative is defined in claim 2, the use of a compound is defined in claim 3, 10 and 11, the pharmaceutical composition is defined in claim 4, the method for the preparation of a parenteral formulation is defined in claim 8. The main objective of the present invention is to provide a new class of compounds of the pyridinium series which are useful for the management of diabetes and aging related vascular complications and particularly in the treatment of complications of diabetes mellitus and other aging related conditions including kidney disease, nerve damage, atherosclerosis, retinopathy and dermatological conditions. The invention also extends the method to reverse the discoloration of teeth resulting from nonenzymatic browning in the oral cavity which comprises administration of an amount effective to reverse the preformed advanced glycosylation crosslinks, etc. Another object of the present invention is to provide compounds of the pyridinium series, which exhibit AGE breaking activities. Yet another object of the present invention is to provide a method of preparation of compounds of the pyridinium series which exhibit AGE breaking activities. Still another object of the invention is to provide pharmaceutical compositions with a new class of compounds of the pyridinium series according to the invention and their pharmaceutically acceptable salts in combination with suitable carriers, solvents, excepients, diluents and other media normally employed in preparing such compositions. Still another object of the invention is to provide a method of treatment of a diabetic patient by administration of the compounds of the invention, either singly or in combination with drugs for antidiabetic therapy, or pharmaceutically acceptable salts thereof in required dosage in admixture with pharmaceutically acceptable diluent, solvent, excepients, carriers or other media as may be appropriate for the purpose. The present invention provides for specific compounds belonging to the class of AGE breakers, of general formula I, wherein R 1 is -R 4 -R 5 or -N(R 7 ) N (R 7 ) R 9 ; R 4 is selected from the group consisting of -N(R 7 )R 6 O-, -N(R 7 )R 6 N(R 7 )-, OR 6 O, and -OR 6 N(R 7 )-, where R 6 is alkyl; R 5 is selected from the group consisting of alkyl, aryl including heteroaryl, -COR 7 , SO 2 R 7 , -C(S) NHR 7 , -C(NH)NHR 7 , -COR 10 , where R 7 is selected from the group consisting of H, alkyl and aryl including heteroaryl provided R 7 might be different for R 1 and R 3 in the same compound; R 2 is selected from the group consisting of F, Cl, Br, I, OR 7 , NO 2 , alkyl, aryl including heteroaryl, formyl, acyl, C(O)NR 7 R 10 , C(O)OR 7 , NR 7 R 10 , N=C(R 7 )(R 10 ), SR 7 , SO 2 NH 2 , SO 2 alkyl and SO 2 aryl, and m is 0, 1 or 2; R 3 is selected from the group consisting of R 7 , OR 7 , N(R 7 )(R 10 ), N=C(R 7 )(R 10 ), N(R 7 )N(R 7 )(R 10 ), N(R 7 ) N=C(R 7 )(R 10 ) and CH(R 7 )C(O)R 8 where R 8 is selected from the group consisting of R 7 , OR 7 and NR 7 R 10 ; R 9 is selected from the group consisting of hydrogen, alkyl, aryl including heteroaryl, C(O)R 10 , -SO 2 R 10 , -C(S)NHR 10 , -C(NH) NH (R 10 ) and -C(O) NHR 10 , R 10 is selected for the group consisting of H, alkyl or aryl including heteroaryl and in each case optionally different from substituent R 10 , provided R 10 might be different for R 1 and R 3 in the same compound; X is selected from group consisting of a halide ion, acetate ion, perchlorate ion, sulfonate ion, oxalate ion, citrate ion, tosylate ion, maleate ion, mesylate ion, carbonate ion, sulfite ion, phosphoric hydrogen ion, phosphonate ion, phosphate ion, BF 4 - and PF 6 - ; The novel compounds of the invention of general formula I having m as 0 or 1 and - COR 1 at position 3 are listed in Table 1A and the novel compounds of the invention of general formula I having m as 0 and - COR 1 at position 4 are listed in Table 1B. These compounds can be further defined by their following chemical names : 1-(2-phenylamino-2-oxoethyl)-4- (phenylsulfonyl hydrazino carbonyl) pyridinium chloride (compound 2); 1-(2-ethoxy -2- oxoethyl) -3-(phenylsulfonyl hydrazino carbonyl) pyridinium bromide (compound 3); 1-(2-(2',4'-dichlorophenyl)-2-oxoethyl)-3-(2(methoxy)ethyloxycarbonyl) pyridinium bromide (Compound 4); 1-(2-phenylamino-2-oxoethyl)-3-((benzoyloxy)ethylaminocarbonyl) pyridinium chloride (compound 5); 1-(2-thien-2'-yl- 2-oxoethyl)-3-(phenylaminocarbonyl hydrazinocarbonyl)pyridinium bromide (compound 6); 1-(2-phenyl-2-oxoethyl)-3-(2-(acetoxy)ethylaminocarbonyl) pyridinium bromide (compound 7); 1-(2-phenylamino-2-oxoethyl)-3-(phenyl sulfonyl hydrazino carbonyl) pyridinimn chloride (compound 8); 1-(2-phenylamino-2-oxoethyl)-3-((4-methylphenyl) sulfonyl hydrazino carbonyl)pyridinium chloride (compound 9); 1-(2-phenyl-2-oxoethyl)-3-(2-(benzoyloxy)ethyloxy carbonyl) pyridinium bromide (compound 10); 1-(2-thien-2'-yl-2-oxoethyl)-3-(phenylcarbonyl hydrazino carbonyl) pyridinium bromide (compound 11); 1-(2-ethoxy-2-oxoethyl)-3-((phenylmethyl)sulfonyl hydrazino carbonyl)pyridinium bromide (compound 12); 1-(2-phenyl-2-oxoethyl)-3-((phenylmethyl)sulfonyl hydrazino carbonyl) pyridinium bromide (compound 13); N, N - bis [3-carbonyl-1-(2-furan-2'-yl-2-oxoethyl) pyridinium] hydrazine dibromide. (Compound No: 14); N,N'-bis [3-carbonyl-1-(2-thien-2'-yl-2-oxoethyl) pyridinium] hydrazine dichloride.(Compound No: 15); 1-(2-phenylamino-2-oxo ethyl)-3-({2-(1-oxo-3-cyclohexyl)-propyl}-hydrazino-carbonyl]-pyridinium bromide.(Compound No: 17); 1-(2-thien-2'-yl-2-oxoethyl)-3-[2-(benzoyloxy)ethylamino carbonyl]-pyridinium bromide (Compound No: 18); 1-(4-ethoxy-2,4-dioxobutyl)-3-(2-(benzoyloxy)ethylamino carbonyl)-pytidinium chloride. (Compound No: 19); 1-(2',4'-dichloro-phenyl-2-oxoethyl)-3-(2-methoxyethyl aminocarbonyl)-pyridinium bromide. (Compound No: 20); N,N'-bis-[3-carbonyl-1-(2-cyclopropylamino-2-oxoethyl) pyridinium] hydrazine dichloride. (Compound No: 21); 1-(2-cyclopropylamino-2-oxoethyl)-3-(2-methoxyethylaminocarbonyl)-pyridinium chloride. (Compound No: 22); 1-(2-thien-2'yl-2-oxoethyl)-3-(2-(2-chloro-3-pyridoylhydrazinocarbonyl) -pyridinium chloride. (Compound No: 24); 1-(2-isopropylamino-2-oxoethyl)-3-(2-methylsulfonylhydrazinocarbonyl) -pyridinium chloride. (Compound No: 25); 1-(2-thien-2'-yl-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride. (Compound No: 27); 1-(2-thien-2'-yl-2-oxoethyl)-3-((2-methoxy ethyl) amino carbonyl)-5-bromo pyridinium chloride (Compound No: 29); 1-(2'-thien-2'-yl-2-oxoethyl)-3-[1-oxo-1-(2-methoxy carbonyl)pyridyl] hydrazino pyridinium chloride. (Compound No: 30); 1-[1-(2-thien-2'-yl-2-oxoethyl)-6-methyl-3-carbonyl pyridinium]-2-[1-(2-Thien-2'-yl-2-oxoethyl)-3-carbonyl pyridinium] hydrazine dichloride(compound no: 31). 1-(2-thien-2'-yl-2-oxoethyl)-3-(isopropylsulfonyl hydrazino carbonyl) pyridinium bromide(compound no: 32). 1-(2-(4-benzyl piperidin-1-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride(compound no: 33). 1-(2-(2-ethoxy carbonyl pyrrolidin-1-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride. (compound no: 34). 1-(2-thien-2'-yl-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl)-5-bromo pyridinium bromide. (compound no: 35). 1-(2-thien-2'-yl-2-oxoethyl)-3-(ethoxycarbonyl hydrazino carbonyl) pyridinium bromide. (compound no: 36). 1-(2-(5-chloro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium bromide (compound no: 37). N,N'-bis[3-carbonyl-1-(2-(4-nitro-thien-2-yl)-2-oxoethyl)pyridinium] hydrazine dichloride. (compound no: 38). 1-(2-thien-2'-yl 2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) -6-methyl pyridinium bromide. (compound no: 39). N,N'-bis[3-carbonyl-1-(2-(5-methyl-thien-2-yl)-2-oxoethyl) pyridinium] hydrazine dichloride. (compound no: 40). N,N'-bis[3-carbonyl-1-(2-(2-ethoxycarbonyl pyrrolidin-1-yl)-2-oxoethyl) pyridinium] hydrazine dichloride. (compound no: 41). 1-[1-(2-thien-2'-yl-2-oxoethyl)-5-aminocarbonyl-3-carbonyl pyridinium]-2-[1-(2-Thien-2'-yl-2-oxoethyl)-3-carbonyl pyridinium] hydrazine dichloride (compound no: 42). 1-(2-(4-carbethoxy-thiazolidin-3-yl)-2oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride (compound no: 43). N,N'-bis[3-carbonyl-1-(2-(5-chloro-thien-2-yl)-2-oxoethyl) pyridinium] hydrazine dichloride. (compound no: 44). 1-(2-(5-methyl-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride (compound no: 45). 1-(2-(4-nitro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium bromide. (compound no: 46). 1-(2-phenylamino-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium chloride (compound no: 47). 1-(2-phenylamino-2-oxoethyl)-4-[2-(benzoyloxy) ethylamino carbonyl] pyridinium chloride (compound no: 48). 1-2-(5-nitro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride (compound no: 49). 1-(2-thien-2'-yl-2-oxoethyl)-3-(trifluoromethanesulfonyl hydrazino carbonyl) - pyridinium bromide. (compound no. 50). 1-(2-thien-2'-yl-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium bromide (compound no.51). 1-(2-thien-2'-yl-2-oxoethyl)-3-(p-methoxy phenyl sulfonyl hydrazino carbonyl) pyridinium bromide (compound no. 52). 1-(2-ethoxy-2-oxoethyl)-3-(phenyl aminocarbonyl hydrazino carbonyl) pyridinium bromide (compound no. 53). 1-(2-ethoxy-2-oxoethyl)-3-(p-toluene sulfonyl hydrazino carbonyl) pyridinium bromide (compound no. 54). 1-(2-phenyl-2-oxoethyl)-3-(phenylamino carbonyl hydrazino carbonyl) pyridinium bromide (compound no. 55). 1-(2-phenylamino-2-oxoethyl)-3-(benzyl sulfonyl hydrazino carbonyl) pyridiniumchloride. (compound no. 56). 1-(2-phenyl-2-oxoethyl)-4-(methanesulfonyl hydrazino carbonyl) pyridinium bromide (compound no. 57). 1-(2-phenyl-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium bromide. (compound no. 58). 1-(2-ethoxy-2-oxoethyl)-4-[2-(benzoyloxy) ethyl amino carbonyl] pyridinium bromide (compound no. 59). 1-(2-ethoxy-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium bromide (compound no. 60). 1-(2-phenyl-2-oxoethyl)-3-(p-methoxyphenyl sulfonyl hydrazino carbonyl) pyridinium bromide. (compound no. 61). 1-(2-phenyl-2-oxoethyl)-4-[2-(benzoyloxy) ethyl amino carbonyl] pyridinium bromide. (compound no. 62). 1-(2-ethoxy-2-oxoethyl)-4-(p-methanesulfonyl hydrazino carbonyl) pyridinium bromide. (compound no. 63). Pyridinium derivatives (having m as 0 or 1 and -COR 1 at position 3) Compound No. R 1 -R 2 -R 3 -X 3 -NHNH-SO 2 Ph - OEt Br 4 -OCH 2 CH 2 OCH 3 - 2,4-dichlorophenyl Br 5 -NHCH 2 CH 2 OCOPh - NH phenyl Cl 6 -NHNHCONHPh - 2-thienyl Br 7 NHCH 2 CH 2 OCOCH 3 - phenyl Br 8 NHNHSO 2 Ph - NH phenyl Cl 9 NHNHSO 2 Ph(4-CH 3 ) - NH phenyl Cl 10 OCH 2 CH 2 OCOPh - phenyl Br 11 -NHNHCOPh - 2-thienyl Br 12 NHNHSO 2 CH 2 Ph - OEt Br 13 NHNHSO 2 CH 2 Ph - phenyl Br 14 Structure (a) - 2-furyl Br 15 Structure-(b) - 2-thienyl Cl 17 NHNHCOCH 2 CH 2 -cyclohexyl - NH-phenyl Cl 18 NHCH 2 CH 2 OCO-phenyl - 2-thienyl Br 19 NHCH 2 CH 2 OCO-phenyl - CH 2 CO 2 -ethyl Cl 20 -NHCH 2 CH 2 OCH 3 - -2,4-dichlorophenyl Br 21 Structure-(c) - NH-cyclopropyl Cl 22 -NHCH 2 CH 2 OCH 3 - NH-cyclopropyl Cl 24 Structure-(e) - 2-thienyl Cl 25 NHNHSO 2 CH 3 - NH-isopropyl Cl 27 NHNHSO 2 CH 3 - 2-thienyl Cl 29 NHCH 2 CH 2 OCH 3 - 2-thienyl Cl 30 Structure-(g) - 2-thienyl Cl 31 Structure - (h) - 2-thienyl Cl 32 . -NHNHSO 2 isopropyl - 2-thienyl Br 33 -NHNHSO 2 CH 3 - Structure (i) Cl 34 -NHNHSO 2 CH 3 - Structure (j) Cl 35 -NHNHSO 2 CH 3 5-Bro mo 2-thienyl Br 36 -NHNHCOC 2 H 5 - 2-thienyl Br 37 -NHNHSO 2 CH 3 - 5-chloro-2-thienyl Br 38 Structure (k) - 4-nitro-2-thienyl Cl 39 -NHNHSO 2 CH 3 6-met hyl 2-thienyl Br 40 Structure (l) - 5-methyl-2-thienyl Cl 41 Structure (m) - Structure (j) Cl 42 Structure (n) - 2-thienyl Cl 43 -NHNHSO 2 CH 3 - Structure (o) Cl 44 Structure (p) - 5-chloro-2-thienyl Cl 45 -NHNHSO 2 CH 3 - 5-methyl-2-thienyl Cl 46 - NHNHSO 2 CH 3 - 4-nitro-2-thienyl Br 47 -NHNHPh - -NHPh Cl 49 -NHNHSO 2 CH 3 - 5-nitro-2-thienyl Cl 50 -NHNHSO 2 CF 3 - 2-thienyl Br 51 -NHNHPh - 2-thienyl Br 52 -NHNHSO 2 -4-methoxy-Phenyl - 2-thienyl Br 53 -NHNHCONHPh - -OEt Br 54 -NHNHSO 2 -4-methyl-Phenyl - -OEt Br 55 -NHNHCONHPh - Ph Br 56 -NHNHSO 2 CH 2 Ph - -NHPh Cl 58 -NHNHPh - Ph Br 60 -NHNHPh - -OEt Br 61 -NHNHSO 2 -4-methoxy-Phenyl - Ph Br Pyridinium derivatives (having m as 0 and -COR 1 at position 4) Compound -R 1 -R 2 -R 3 -X 2 NHNHSO 2 Ph - NH phenyl Cl 48 -NHCH 2 CH 2 OCOPh - -NHPh Cl 57 -NHNHSO 2 CH 3 - -Ph Br 59 -NHCH 2 CH 2 OCOPh - -OEt Br 62 -NHCH 2 CH 2 OCOPh - -Ph Br 63 -NHNHSO 2 CH 3 - -OEt Br According to the embodiment of the present invention, the present compounds are used for the treatment of diabetic complications, and aging related complications including kidney disease, nerve damage, atherosclerosis, retinopathy, dermatological conditions and colouration of teeth occurring due to the higher levels of preformed AGE. The increased levels of preformed AGE can be brought under control by breaking the AGE products using compounds mentioned in the invention. The invention also provides a process for the preparation of novel compounds of the pyridinium series. The said process for the preparation of compound 15, comprises, adding a solution of 2-chloro acetylthiophene in isopropanol to N,N-bis-(nicotinyl)hydrazine dissolved in methanol, refluxing for six hours, cooling, filtering the precipitated solid, washing the solid with hot ethyl acetate and finally purifying the solid with 20 ml of methanol : ethyl acetate (3 : 1) to yield the desired compound. Similarly, the other novel compounds are prepared from properly substituted pyridine derivatives followed by quarternization with appropriate reagent by refluxing in alcoholic solvents like, methanol, ethanol, propanol, etc and high boiling solvents like toluene or xylene etc, for 6 - 48 hrs. to give the desired compounds. The examples of substituted pyridine derivatives which can be used for preparation of specific compounds of the invention are given below: 1. N,N'-bis(nicotinyl)hydrazine 2. 3-[(2-pyridyl)hydrazinocarbonyl]pyridine 3. 3-[(2-methanesulfonyl)hydrazinocarbonyl]pyridine 4. 3-[(2-benzoyloxy)ethylaminocarbonyl]pyridine 5. 3-[(2-phyenylsulfonyl)hydrazinocarbonyl]pyridine 6. 3-[(2-acetoxy)ethyloxycarbonyl]pyridine 7. 3-[(2-benzoyloxy)ethyloxycarbonyl]pyridine 8. 3-[(2-methoxy)ethyloxycarbonyl]pyridine 9. 3-[(2-phyenylaminocarbonyl)hydrazinocarbonyl]pyridine 10. 3-[(2-acetoxy)ethylaminocarbonyl]pyridine 11. 3-[(2-(4-methylphenyl sulfonyl)hydrazinocarbonyl)]pyridine 12. 3-[(2-benzoyl)- hydrazino carbonyl]pyridine 13. 3-[(2-phenylmethane sulfonyl) hydrazino carbonyl]pyridine 14. 3-[(2-(3- cyclohexylpropanoyl) hydrazino carbonyl]pyridine 15. 3-[(2-methoxy)ethylaminocarbonyl]pyridine 16. 3-[1-oxo-1-(2-methoxycarbonyl)pyridyl]hydrazino pyridine The examples of quaternizing agents which may be used in the reaction are given below: 1. 2-bromoacetyl thiophene 2. 2-chloroacetyl thiopene 3. phenacylbromide 4. phenacylchloride 5. 2,4-dichloropheanacylbromide 6. N- phenyl chloroacetamide 7. N- cyclopropyl chloroacetamide 8. ethylbromoacetate 9. bromo acetylfuran 10. N- isopropylchloroacetamide 11. N- chloroacetyl-2-pyrrolidinone 12. chloroacetic acid In-vitro screening for AGE-breaking Activity The in vitro AGE formation, studied in the laboratory, by incubating reducing sugar glucose, with protein bovine serum albumin, resulted in browning of solution and increase in the fluorescence. Fluorescence was used as the criteria to monitor the increased AGE formation. Example 1 AGE breaker activity has been confirmed by the screening procedure as mentioned below: Materials: Bovine serum albumin (fraction V) (BSA) Glucose, analytical grade Phosphate buffered saline (PBS) Equipment: Microplate ELISA Reader - Spectramax Plus (Molecular Devices, USA) Microplate washer, (Bio -Tec Instruments, USA) pH meter Methods of experiment: Elisa (Enzyme Linked Immunosorbent Assay) 160 mg/ml of protein, bovine serum albumin, BSA and 1.6M glucose sugar were dissolved in phosphate buffered saline, PBS. Sodium azide was added at 0.02% concentration as a preservative. The solution was filtered asceptically through a 0.22 µM filter and kept for aging at 37°C for 16 weeks. After 16 weeks the solution was dialyzed against PBS, aliquoted and stored at - 20°C. To determine the AGE breaking activity, 10µg/ml of the 16 weeks AGE-BSA was incubated with different concentrations of the test compounds at 37°C for 24 hours and AGE breaking activity of the test compounds by ELISA was determined. ELISA was performed as follows: 1. Different concentrations of 16 weeks AGE-BSA were coated on a microtitre plate as standard. Each concentration is coated in triplicates. 2. The test samples were coated on microtitre plate at a concentration of 5 ng. to 20 ng per well in triplicates. 3. The plate was incubated at 37°C for one hour. 4. After incubation the plate was washed with PBST (PBS with 0.05% Tween 20). 5. Blocking with 5% skimmed milk in PBS at 37°C for one hour was done. 6. The plate was washed with PBST. 7. Primary antibody against AGE-BSA was added and the plate is incubated at 37°C for one hour. 8. The plate was washed with PBST 9. Secondary antibody anti rabbit HRPO (Horse-Radish Per Oxidase) conjugate was added and the plate is incubated at 37°C for one hour. 10. The plate was washed with PBST. 11. Colour development with OPD (orthophenylenediamine dihydrochloride) and hydrogen peroxide was done. 12. OD (optical density) at (450nm reading - 620nm reading) was measured after incubation at 37°C for 15 minutes with Microplate ELISA Reader. The breaker activity of the compounds were determined by the following formula: % Breaker activity = OD 450-620 Control - OD 450-620 Test OD 450-620 Control x 100 OD 450-620 Control= Absorbance of 20ng AGE-BSA after incubation at 37°C for 24 hours without test compound OD 450-620 Test= Absorbance of 20ng AGE-BSA after incubation at 37°C for 24 hours with required concentration of test compound Using specific examples, the % AGE breaking activity was calculated and recorded in Table 2. Sample Concentration (mM) % Breakage PTB 10 27 20 47 Compound 4 10 13 25 41 Compound 5 10 37 25 90 Compound 14 10 14 Compound 15 5 20 Compound 20 5 17.66 Compound 21 5 22.8 Compound 22 10 12.38 Compound 24 10 12.51 Compound 25 10 10.85 Compound 27 10 17.53 Compound 29 10 32.38 Compound 31 2.5 85.67 Compound 32 10 31.45 Compound 33 10 20.94 Compound 34 10 25.34 Compound 35 2.5 29.36 Compound 36 10 33.43 Compound 37 10 40.85 Compound 38 10 75.92 Compound 39 1.0 77.69 Compound 40 10 81.95 Compound 41 10 20.31 Compound 42 1 95.36 Compound 43 10 25.06 Compound 44 10 78.41 Compound 45 10 25.17 Compound 46 10 60.94 Compound 47 2.5 68.35 Compound 48 10 19.07 Compound 49 1 42.01 Compound 50 10 92.64 Hence compounds 5, 29,31,32, 35, 36-40, 42, 44, 46,47, 49 and 50 have superior AGE breaking activity compared to PTB, of which the potency of compounds 31, 38-40, 42, 44, 46, 47, 49 and 50 are significantly much higher. In-vivo screening for AGE-breaking Activity : The test compounds were studied for their beneficial effects on diabetic neuropathy and nephropathy in a rat model of diabetes. The rats were divided into three groups. The first group consisted of age matched untreated non-diabetic animals. The second group consisted of diabetic controls and the third group was the diabetic group treated with the test compound. Each treatment group had its own corresponding control and diabetic groups. The second and third groups were treated with Streptozotocin (STZ) at 60mg/kg for the induction of diabetes. After completion of 12 weeks of diabetes the rats were treated with the test compound daily (doses shown in table) for a period of 8 weeks. At the end of the treatment the creatinine clearances and nerve conduction velocities (NCV) of the animals were estimated. Creatinine clearances of the rats were estimated as follows Creatinine clearance = Concentration of creatinine in the urine Concentration of creatinine in the blood. x ml urine passed/minute The creatinine clearance in untreated diabetic group was compared with the treated group and the percentage improvements are shown in the Table 3. The nerve conduction velocity was measured using a modified method of Biro et al 1998. Briefly under ether anesthesia the sciatic and tibial nerves were electrically stimulated at the sciatic notch or ankle, respectively. Electromyograms (EMG's) recorded from the plantar muscles consisted of two components: (1) the short latency direct motor response (M) and the monosynaptically elicited long-latency sensory response (H, Hoffmann reflex). Latency and the duration of the M responses were measured and the motor nerve conduction velocity (MNCV) was calculated as follows : MNCV = Distance between the sciatic and tibial stimulation points Differences of the latency for M sciatic and M tibial . The percentage improvement in the nerve conduction velocities in the group treated with the test compounds was calculated as follows: % Improvement in the NCV's = NCV of the treated group - NCV of the diabetic group NCV of the control group - NCV of the diabetic group. Effect of compound Nos 14 and 21 on the creatinine clearance and nerve conduction velocities: Parameters Compound No.15 (7.5 mg/kg, b.i.d.) Compound No.21 (6.0 mg/kg, b.i.d.) % Increase in creatinine clearance 103.0 5.0 % Increase in the NCV 60.0 58.4 The results show that compounds of this class have beneficial effects on creatinine clearance and nerve conduction velocities. Discussion of the test results: All the test compounds mentioned in the current application have shown an invitro AGE-breaker effect. Under conditions of chronic hyperglycemia in rats there is a spontaneous non-enzymatic reaction between glucose, lipids and proteins that leads to the formation of advanced glycosylation end products. In this animal model decreased creatinine clearance and decreased nerve conduction velocity have been demonstrated. These changes are related to damage to renal and neuronal tissues. During chronic NIDDM patients, there is a decrease in the creatinine clearances as a manifestation of the diabetes induced renal damage. One of the major factors contributing to renal damage is the glycation of the long-lived proteins in the kidney. It is well recognized that there is a decrease in the nerve conduction velocities in chronic diabetic subjects, which is a manifestation of neuropathy. Breaking of cross-linked proteins in the neuronal tissues and associated vasculature could lead to an improvement in the neuronal function. The compounds of the present invention have shown a functional improvement both in terms of the improvement in the creatinine clearance and an improvement in the nerve conduction velocities. The evidences stated above clearly demonstrate that these compounds could play a major role in the prevention and treatment of various diabetic and aging related complications like nephropathy and neuropathy. The following examples give method of preparation of the specific novel compounds of the invention as given in Table 1. Reference Example 1-(2-Ethoxy-2-oxoethyl)-4-(phenylsulfonyl hydrazino carbonyl) pyridinium bromide: To a boiling solution of N-(benzene sulfonyl)-isonicotinic hydrazide (1.0g.,0.036 mol.) in isopropanol (25 ml), a solution of ethyl bromo acetate (0.6g., 0.036 mol.) in 10ml isopropanol was added and the reaction mixture was refluxed for 24 hrs. The reaction mixture was concentrated under vacuum (~10ml.) and was recrystalized from a mixture of methanol-ethyl acetate (3:1, 15ml.) to afford the solid. The solid was further washed with (10ml.) ethyl acetate yielding 1.05 g of required product. Yield 60% m.p. 171 - 173°C. IR (KBr, cm -1 ) 1745, 1685, 1645. 1 HNMR (DMSOd 6 , 400 MHz) δ 11.41 (1H, s), 10.39 (1H, s), 9.10 (2H, d), 8.27 (2H, d), 7.82 - 7.80 (2H, d), 7.60 - 7.57 (1H, t), 7.50 - 7.46 (2H, t), 5.63 (2H, s), 4.18 - 4.12 (2H, q), 1.19 - 1.15 (3H, t). Mass (m/z) 364, 365, 366 According to the above mentioned procedure, the following compounds are synthesized by reacting the corresponding pyridine derivatives with appropriate reagents by refluxing in methanol, ethanol, propanol, toluene of xylene for 6 - 48 hrs. to get the desired compounds. Example 3 1-(2-Phenylamino-2-oxoethyl)-4-(phenylsulfonyl hydrazino carbonyl) pyridinium chloride (Compound 2): Yield 10% m.p. 225 - 227°C. IR (KBr, cm -1 ) 1693, 1642, 1592 1 HNMR(DMSOd 6 , 400 MHz) δ 11.55 (1H, s), 10.99 (1H, s), 10.49 (1H, s), 9.20 (2H, d), 8.34 (2H, d), 7.89 (2H,d), 7.73 - 7.64 (1H, t), 7.61 - 7.56 (4H, m), 7.37 - 7.33 (2H, t), 7.12 - 7.09 (1H, t), 5.73 (2H, s). Mass (m/z) 411, 412, 413, 414 Example 4 1-(2-Ethoxy-2-oxoethyl)-3-(phenylsulfonylhydrazino carbonyl) pyridinium bromide (Compound 3): Yield 75% m.p. 145 - 147 °C. IR(KBr cm -1 ) 1744, 1713, 1633 1 HNMR (DMSOd 6 , 400MHz) δ 11.27(1H,s),10.36 (1H, s), 9.28(1H,s), 9.09(1H,d), 8.83(1H,d),8.27 - 8.24 (1H,m), 7.82 - 7.79 (2H,m), 7.58 (1H,t), 7.48 (2H, t), 5.59 (2H, s), 4.17 - 4.12 (2H, q), 1.16(3H,t). Mass (m/z) 364, 365, 366 Example 5 1-(2-(2',4'-Dichlorophenyl)-2-oxoethyl)-3-(2(methoxy)ethyloxycarbonyl) pyridinium bromide (Compound 4): Yield 25% m.p. 156 - 158°C. IR (KBr, cm -1 ) 1731, 1706, 1640 1 HNMR (DMSO d 6 ,400 MHz)δ 9.61 (1H, s),9.20(1H, d),9.13 (1H,d), 8.45 - 8.41 (1H, m),8.15 (1H, d),7.92(1H, d),7.78 - 7.76 (1H, m), 6.49 (2H, s), 4.56 - 4.54 (2H, m), 3.72 - 3.69 (2H, q), 3.31 (3H, s). Mass (m/z) 368, 369, 370, 371 Example 6 1-(2-Phenylamino-2-oxoethyl)-3-(2-(benzoyloxyl) ethylaminocarbonyl) pyridinium chloride (Compound 5): Yield 70% m.p. 171 -172°C IR (KBr, cm -1 ) 1720, 1692, 1668 1 HNMR : (DMSOd 6 , 400 MHz) δ 11.06 (1H, s), 9.67 (1H, t), 9.59 (1H, s), 9.20 (1H,d), 9.11 (1H, d), 8.36 - 8.32(1H, m), 8.00 (2H, d), 7.66 - 7.61 (3H, m),7.51 (2H, t),7.34 (2H, t), 7.10 (1H, t), 5.77 (2H,s), 4.45 (2H,t), 3.76 - 3.72 (2H, q). Mass (m/z) 404, 405, 406, 407 Example 7 1-(2-Thien-2'-yl-2-oxoethyl)-3-(phenylaminocarbonyl hydrazinocarbonyl) pyridinium bromide (Compound 6): Yield 30% m.p. 202 - 204°C. IR (KBr, cm -1 ) 1718, 1673 1 HNMR : (DMSOd 6 , 400 MHz) δ 11.03 (1H, s), 9.55 (1H, s), 9.18 (1H, d), 9.10 (1H, d), 9.00 (1H, s),8.57 (1H,s), 8.46 - 8.42 (1H, t), 8.25 - 8.22 (2H, m), 7.47 - 7.45 (2H, d), 7.43 - 7.41 (1H, t), 7.29 -7.25 (2H, t), 7.0 - 6.96 (1H, t), 6.46 (2H, s). Mass (m/z) 381,382,383 Example 8 1-(2-Phenyl-2-oxoethyl)-3-(2-(acetoxy) ethylaminocarbonyl) pyridinium bromide (Compound 7 ): Yield 55% m.p. 186 - 188 IR (KBr, cm -1 ) 1734, 1697, 1679 1 HNMR (DMSOd 6 , 400 MHz) δ 9.47(1H,s), 9.36 (1H,t), 9.13 - 9.05 (2H, m), 8.42 - 8.38 (1H, m), 8.06 (2H, d), 7.80 (1H, t), 7.67 (2H, t), 6.54 (2H, s), 4.18 (2H,t), 3.61 - 3.57 (2H,q), 2.02 (3H,s). Mass (m/z) 327, 328, 329. Example 9 1-(2-Phenylamino-2-oxoethyl)-3-(phenyl sulfonyl hydrazino carbonyl) pyridinium chloride (Compound 8): Yield 38% m.p. 232 - 234°C. IR (KBr, cm -1 ) 1689, 1636, 1596 1 HNMR (DMSOd 6 , 400 MHz) δ 11.30 (1H, s), 10.80 (1H, s), 10.37 (1H, s), 9.29 (1H, s), 9.09 (1H, d), 8.81 (1H, d), 8.25 - 8.21 (1H, t), 7.82 - 7.80 (2H, d), 7.59 - 7.46 (5H, m), 7.28 - 7.24 (2H, t), 7.04 -7.00 (1H, t), 5.62 (2H,s). Mass (m/z) 411, 412, 413, 414 Example 10 1-(2-Phenylamino-2-oxoethyl)-3-((4-methylphenyl)sulfonyl hydrazino carbonyl) pyridinium chloride (Compound 9): Yield 48% m.p. 205 - 206°C IR(KBr, cm -1 ) 1712, 1681, 1632 1 HNMR (DMSOd 6 , 400 MHz) δ 11.35 (1H, s), 10.86 (1H, s), 10.36 (1H, s), 9.38 (1H, s), 9.17 (1H, d), 8.90 (1H,d), 8.34 - 8.30 (1H, m), 7.78 - (2H,d), 7.59 (2H, d), 7.37 - 7.33 (4H,m), 7.11 (1H,t), 5.70 (2H,s), 2.36 (3H, s). Mass (m/z) 425, 426, 427, 428 Example 11 1-(2-Phenyl-2-oxoethyl)-3-(2-(benzoyloxy)ethyloxy carbonyl) pyridinium bromide (Compound 10): Yield 35% m.p. 132 -134°C. IR (KBr, cm -1 ) 1730, 1705, 1690 1 HNMR (DMSOd 6 , 400 MHz) δ 9.80 (1H, s), 9.36 (1H, d), 9.30 (1H, d), 8.58 (1H, t), 8.21 (2H, d), 8.12 (2H, d), 7.95 (1H, t), 7.85 - 7.80 (3 H, m), 7.68 (2H, t), 6.71 (2H, s), 4.95 - 4.93 (2H, m), 4.82 - 4.80 (2H, m). Mass (m/z) 390, 391, 392. Example 12 1-(2-Thien-2'-yl-2-oxoethyl)-3-(phenylcarbonyl hydrazino carbonyl) pyridinium bromide (Compound 11): Yield 45% m.p. 80 - 81 °C IR(KBr Cm -1 ) 1700, 1663, 1631 1 HNMR (DMSOd 6 , 400MHz) δ 11.49 (1H, s), 10.95 (1H, s), 9.67 (1H, s), 9.34 (1H, d), 9.27 (1H, d), 8.52 - 8.48 (1H, m), 8.29 - 8.28 (2H, m), 8.00 (2H, d), 7.68 (1H, t), 7.59 (2H, t), 7.46 (1H, t), 6.63 (2H,s) Mass (m/z) 366, 367, 368, 369 Example 13 1-(2-Ethoxy-2-oxoethyl)-3-((phenylmethyl)sulfonyl hydrazino carbonyl) pyridinium bromide (Compound 12): Yield 50% m.p. 147 - 148°C IR (KBr, cm -1 ) 1749, 1698, 1640 1 HNMR (DMSOd 6 , 400 MHz) δ 11.57 (1H, s), 10.21 (1H,s), 9.75 (1H,s), 9.38 (1H, d), 9.24 (1H, d), 8.59 - 8.56(1H, m), 7.67 - 7.65 (2H, m), 7.58 - 7.52 (3H, m), 5.90(2H, s),4.68 (2H, s), 4.45 - 4.39(2H, q),1.43 (3H, t). Mass (m/z) 377, 378, 379 Example 14 1-(2-Phenyl-2-oxoethyl)-3-((phenylmethyl)sulfonyl hydrazino carbonyl)pyridinium bromide (Compound 13): Yield 80% m.p. 205 - 207° C IR (KBr, Cm -1 ) 1657, 1637 1 HNMR (DMSOd 6 , 400 MHz) δ 11.59 (1H,s), 10.20 (1H,s), 9.71 (1H,s), 9.33 (1H, d), 9.27 (1H, d), 8.62 - 8.59(1H, m), 8.25 - 8.23 (2H, d), 7.99 -7.95 (1H, t), 7.86 - 7.82 (2H, t), 7.67 - 7.65 (2H, m), 7.57 - 7.52 (3H, m),6.72 (2H, s), 4.69 (2H, s). Mass (m/z) 410, 411, 412, 413 Example 15 N, N' - Bis [3-carbonyl-1-(2-furan-2'-yl-2-oxoethyl) pyridinium] hydrazine dibromide. (Compound No: 14) Yield 23% m.p. 267-269 °C (dec) IR (KBr, cm -1 ) 1687,1660 1 H NMR (DMSO d 6 , 400 MHz) ä 11.65 (2H,s), 9.56 (2H,s), 9.21 - 9.15 (4H,m), 8.48-8.44 (2H,t), 8.23 (2H,s), 7.74 - 7.73 (2H,d), 6.91 - 6.90 (2H,d) 6.34 (4H,s) Mass (m/z) 459, 460, 461 Example 16 N,N'-Bis [3-carbonyl-1-(2-thien-2'-yl-2-oxoethyl) pyridinium] hydrazine dichloride.(Compound No: 15) Yield 35% m.p. 275-277 °C IR (KBr, cm -1 ) 3374, 1665,1632, 1410 1 H NMR (DMSO d 6 , 400 MHz) ä 11.88 (2H,s), 9.66 (2H,s), 9.29 - 9.24 (4H,m), 8.48 - 8.44 (2H,m), 8.25 - 8.23 (4H,m), 7.43 - 7.41 (2H,m), 6.53 (4H,s). Mass (m/z) 491, 492, 493, 494 Example 18 1-(2-Phenylamino-2-oxo ethyl)-3-({2-(1-oxo-3-cyclohexyl)-propyl} hydrazino-carbonyl}-pyridinium bromide.(Compound No: 17); Yield 25% m.p 234-236 °C (dec) IR (KBr, cm -1 ) 1689, 1652 and 1625 1 H NMR (DMSO d 6 , 400 MHz) δ 11.11 (1H,s), 10.95 (1H,s), 10.23 (1H,s), 9.56 (1H,s), 9.23 - 9.21 (1H,d), 9.06 - 9.04 (1H,d), 8.38-8.35 (1H,m), 7.62 - 7.60 (2H,d), 7.37 - 7.33 (2H,t), 7.12 - 7.09 (1H,t), 5.75 (2H,s), 2.25 - 2.22 (2H,t), 1.72 - 1.60 (5H,m) 1.49 - 1.43 (2H,m), 1.25 - 1.10 (4H,m), 0.91 - 0.83 (2H,m) Mass (m/z) 409, 410, 411 and 412 Example 19 1-(2-Thien-2'-yl-2-oxoethyl)-3-[2-(benzoyloxy)ethylamino carbonyl]-pyridinium bromide (Compound No:18); Yield 40% m.p. 125-127°C IR (KBr, cm -1 ) 1710 and 1675 1 H NMR (DMSO d 6 , 400 MHz) δ 9.48 (1H,s), 9.43 - 9.41 (1H,t), 9.12 - 9.11 (1H,d), 9.05 - 9.02 (1H,d), 8.40 - 8.36 (1H,m), 8.25 - 8.20 (2H,m), 8.00 - 7.98 (2H,m), 7.68 - 7.64 (1H,m), 7.54-750 (2H,m), 7.42 - 7.40 (1H,m), 6.43 (2H,s), 4.46-4.43 (2H,t), 3.77-3.73 (2H,q) Mass (m/z) 395, 396, 397 and 398 Example 20 1-(4-Ethoxy-2, 4-dioxobutyl)-3-(2-(benzoxyloxy)ethylamino carbonyl)-pyridinium chloride. (Compound No: 19); Yield 35% m.p. 147-149°C IR (KBr, cm -1 ) 1743, 1720, 1680 and 1627 1 H NMR (DMSO d 6 , 400 MHz) δ 9.62 - 9.59 (1H,t), 9.32 - 9.29 (1H,s), 9.05 - 9.03 (1H,d), 8.93 - 8.90 (1H,d), 8.27 - 8.24 (1H,m), 7.92 - 7.89 (2H,d), 7.59 - 7.55 (1H,m), 7.45 - 7.41 (2H,m), 5.82 (2H,s), 4.37-4.34 (2H,t), 4.08-4.03 (2H,q), 3.80 (2H,s), 3.67-3.63 (2H,q), 1.15-1.11 (3H,t), Mass (m/z) 399, 400 and 401 Example 21 1-(2',4'-Dichloro-phenyl-2-oxoethyl)-3-(2-methoxyethyl aminocarbonyl)-pyridinium bromide. (Compound No: 20); Yield 70% m.p. 93-95 °C IR (KBr, cm -1 ) 1704, 1664 and 1636 1 H NMR (DMSO d 6 , 400 MHz) δ 9.48 (1H,s), 9.29 (1H,bs), 9.11 - 9.08 (2H,m), 8.41 - 8.38 (1H,m), 8.15 - 8.13 (1H,d), 7.92 - 7.91 (1H,t), 7.78 - 7.75 (1H,m), 6.44 (2Hs,) 3.52 (2H,bs), 3.51 (2H,bs), 3.28 (3H,s) Mass (m/z) 367,368,369 and 370 Example 22 N,N'-Bis-[3-carbonyl-1-(2-cyclopropylamino-2-oxoethyl) pyridinium] hydrazine dichloride. (Compound No: 21); Yield 40% m.p. 228-230 °C IR (KBr cm -1 ) 1675,1636 and 1298 1 H NMR (DMSO d 6 , 400 MHz) δ 11.85 (2H,s), 9.59 (2H,s), 9.25 - 9.19 (4H,m), 9.00 - 8.99 (2H,d), 8.39 - 8.36 (2H,m), 5.53 (4H,s), 2.73 -2.66 (2H,m), 0.78 - 0.62 (4H,m), 0.53 - 0.49 (4H,m) Mass (m/z) 437, 438 and 439 Example 23 1-(2-Cyclopropylamino-2-oxoethyl)-3-(2-methoxyethylaminocarbonyl)-pyridinium chloride. (Compound No: 22); Yield 10% m.p. 122-124 °C IR (KBr, cm -1 ) 1661, 1633, 1549 and 1121 1 H NMR (DMSO d 6 , 400 MHz) δ 9.40 (1H,s), 9.08 - 9.02 (2H,m), 8.28 - 8.25 (1H,m), 5.53 (2H,s), 3.66 - 3.61 (4H,m), 3.39 (3H,s), 2.78 - 2.74 (1H,m), 0.80 - 0.75 (2H,m), 0.64 - 0.61 (2H,m) Mass (m/z) 278, 279 and 280 Example 25 1-(2-Thien-2'yl-2-oxoethyl)-3-(2-(2-chloro-3-pyridoylhydrazinocarbonyl)-pyridinium chloride. (Compound No: 24); Yield 56% m.p. 233-235 °C IR (KBr, cm -1 ) 1680,1637,1404 and 1293 1 H NMR (DMSO d 6 , 400 MHz) δ 11.62 (1H,s), 11.05 (1H,s), 9.62 (1H,s), 9.24 - 9.23 (1H,d), 9.18 - 9.16 (1H,d), 8.58 - 8.56 (1H,m), 8.46 - 8.43 (1H,m), 8.26 - 8.24 (2H,m), 8.02 - 8.00 (1H,m), 7.61-7.58 (1H,m), 7.43 - 7.41 (1H,m), 6.51 (2H,s) Mass (m/z) 401, 402, 403, 404 and 405 Example 26 1-(2-Isopropylamino-2-oxoethyl)-3-(2-methylsulfonylhydrazinocarbonyl)-pyridinium chloride. (Compound No: 25; Yield 10% m.p. 227 - 229 °C IR (KBr, cm -1 ) 1691, 1670, 1566 and 1330 1 H NMR (DMSO d 6 , 400 MHz) δ 11.55 (1H,s), 9.94 (1H,s), 9.52 (1H,s), 9.16 - 9.14 (1H,m), 9.09 - 9.07 (1H,m), 8.72 - 8.70 (1H,m), 8.34 - 8.30 (1H,m), 5.50 (2H,s), 3.89 - 3.84 (1H,m), 3.11 (3H,s), 1.13 - 1.12 (6H,d) Mass (m/z) 315, 316 and 317 Example 28 1-(2-Thien-2'-yl-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride (Compound No: 27); Yield 31.00% m.p. 215- 217°C IR (KBr, cm -1 ) 1685, 1666 and 1635 1 HNMR :(DMSO d 6 , 400 MH z ) δ 11.49, (1H, s), 9.96 (1H, s), 9.55 (1H, s), 9.18 (1H, d), 9.10 (1H, d), 8.43 - 8.39 (1H, t), 8.25 - 8.22 (2H, m), 7.42 (1H, t) 6.47 (2H, s), 3.09 (3H, s). Mass (m/z) 340, 341, 342 and 343 Example 30 1-(2-Thien-2'-yl-2-oxoethyl)-3-((2-methoxy ethyl) amino carbonyl)-5-bromo pyridinium chloride (Compound No: 29); Yield 31.00% m.p. 180 - 182°C IR (KBr, cm -1 ) 1661 and 1620 1 HNMR (DMSO d 6 , 400 MH z ) δ 9.58 - 9.54 (2H, d), 9.43 - 9.39 (2H, d), 8.25 - 8.21 (2H, m), 7.41 (1H, t), 6.43 (2H, s), 3.51 (4H, m), 3.29 (3H, s). Mass (m/z) 384, 385, 386, 387 and 388 Example 31 1-(2-Thien-2'-yl-2-oxoethyl)-3-[1-oxo-1-(2-methoxycarbonyl) pyridyl] hydrazino pyridinium chloride (Compound No: 30); Yield 30.00% m.p. 222 - 225°C IR (KBr, cm -1 ) 1726, 1708 and 1662 1 H NMR (DMSO d 6 , 400 MH z ) δ 11.47 (1H, s), 11.23 (1H, s), 9.58 (1H, s), 9.22 - 9.15 (3H, m), 8.56 - 8.53 (1H, d), 8.46 - 8.43 (1H, t) 8.25 - 8.21 (3H, m), 7.42 (1H, t), 6.49 (2H, s), 3.95 (3H, s) Mass (m/z) 425, 426 and 427 Example 32 1-[1-(2-Thien-2'-yl-2-oxoethyl)-6methyl-3-carbonyl pyridinium]-2-[1-(2-Thien-2'-yl-2-oxoethyl)-3-carbonyl pyridinium] hydrazine dichloride(compound no: 31), Yield 40% M.P. 76-80 °c (dec) IR (KBr,cm -1 ) 1637,1513 1 HNMR (DMSO d 6 , 400 MHz) δ 11.69(2H,s), 9.59-9.53(2H,d), 9.19(2H,m), 9.05(1H,d), 8.46-8.43(1H,t) ,8.34(1H,d), 8.27-8.23(4H,m), 7.45-7.41 (2H,m) ,6.56(2H,s) ,6.48(2H,s) ,2.81(3H,s). Mass(m/z) 505,506,507. Example 33 1-(2-Thien-2'-yl-2-oxoethyl)-3-(isopropylsulfonyl hydrazino carbonyl) pyridinium bromide(compound no: 32), Yield 70% M.P 90-95°c (dec) IR (KBr,cm -1 ) 1638,1589 1 HNMR (DMSO d 6 , 400 MHz) δ 11.27(1H,s),9.91(1H,s), 9.60(1H,s) ,9.19-9.15(2H,m), 8.42-8.36(1H,m) ,8.25-8.21(2H,m) ,7.43-7.41(1H,t) ,6.45(2H,s), 1.35-1.34(6H,d). Mass(m/z) 368,369,370 Example 34 1-(2-(4-Benzyl piperidin-1-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride(compound no: 33 ), Yield 17% M.P 76-78°c IR (KBr,cm -1 ) 1684,1650,1556,1540. 1 HNMR (DMSO d 6 , 400 MHz) δ 11.46(1H,s) ,9.55(1H,s) ,9.46(1H,s) ,9.09-9.03(2H,m), 8.36-8.32(1H,t), 7.33-7.29(2H,m), 7.23-7.19(3H,m), 5.88-5.79(2H,m) ,4.30-4.27(1H,d) ,3.76-3.73(1H,d), 3.10(4H,m) ,2.64(1H,t) ,2.57-2.55(2H,d), 1.85(1H,bs) ,1.72-1.63(2H,t) ,1.36-1.28(1H,q) ,1.13-1.03(1H,m) Mass(m/z) 431,432,433 Example 35 1-(2-(2-Ethoxy carbonyl pyrrolidin-1-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride. (compound no: 34), Yield 14% M.P 88-91°c IR (KBr,cm -1 ) 1735,1665,1539 1 HNMR (DMSO d 6 , 400 MHz) δ 11.48(1H,s) ,9.96(1H,s) ,9.46(1H,s) ,9.09-9.05(2H,m) ,8.38-8.34(1H,t), 5.94-5.80(2H,q) ,4.37-4.36(1H,d), 4.08-4.06(2H,d), 3.68-3.65(2H,m), 3.09(4H,m) ,2.23-2.18(2H,m), 2.04 -1.93(3H,m) ,1.18-1.09(3H,t) Mass(m/z) 399,400,401 Example 36 1-(2-Thien-2'-yl-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl)-5-bromo pyridinium bromide. (compound no: 35), Yield 54% M.P Above 190-195°c(dec) IR (KBr,cm -1 ) 1682,1557,1540,1520 1 HNMR (DMSO d 6 , 400 MHz) δ 11.35(1H,s) ,10.01(1H,s) ,9.57-9.54(2H,d), 9.32(1H,s) , 8.26-8.22(2H,m), 7.42(1H,s), 6.39(2H,s), 3.08(3H,s) Mass (m/z) 418,419,420 Example 37 1-(2-Thien-2'-yl-2-oxoethyl)-3-(ethoxycarbonyl hydrazino carbonyl) pyridinium bromide. (compound no: 36), Yield 69% M.P 155-157°c IR (KBr,cm -1 ) 1731,1665,1637 1 HNMR (DMSO d 6 , 400 MHz) δ 11.04(1H,s) , 9.59(1H,s) , 9.53(1H,s) , 9.18(1H,s) , 9.05-9.04(1H,d) , 8.42(1H,s) , 8.25-8.23(2H,m) , 7.43(1H,s) , 6.46(2H,s), 4.12-4.11(2H,s), 1.23(3H,s) Mass (m/z) 334,335,336 Example 38 1-(2-(5-chloro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium bromide (compound no: 37), Yield 87% M.P 228-230°c IR (KBr,cm -1 ) 1708,1664,1631,1550 1 HNMR (DMSO d 6 , 400 MHz) δ 11.40(1H,s) , 9.98(1H,s) , 9.50(1H,s) , 9.15(1H,d) , 9.061 H,d), 8.43-8.39(1H,t) , 8.16-8.15(1H,d), 7.51-7.50(1H,d) , 6.41(2H,s) , 3.09 (3H,s) Mass (m/z) 374,375,376,377 Example 39 N-N'-Bis[3-carbonyl-1-(2-(4-nitro-thien-2-yl)-2-oxoethyl)pyridinium] hydrazine dichloride. (compound no: 38), Yield 27% M.P 204-207°c IR (KBr,cm -1 ) 1681,1539,1514 1 HNMR (DMSO d 6 , 400 MHz) δ 11.90(2H,s) , 9.63(2H,s) , 9.31-9.30(4H,m) , 9.24 -9.22(2H,m), 8.87(2H,s) , 8.49-8.46(2H,t), 6.56 (4H,s) Mass (m/z) 581,582,583 Example 40 1-(2-Thien-2'-yl-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) -6-methyl pyridinium bromide. (compound no: 39), Yield 14% M.P 90-95°c(dec) IR (KBr,cm -1 ) 1677,1575 1 HNMR (DMSO d 6 , 400 MHz) δ 11.32(1H,s), 9.97(1H,s) 9.52(1H,s) , 8.94-8.92(1H,d) , 8.32-8.24(3H,m) , 7.44(1H,t) , 6.54(2H,s), 3.08(3H,s), 2.79(3H,s) Mass (m/z) 354,355,356 Example 41 N-N'-Bis[3-carbonyl-1-(2-(5-methyl-thien-2-yl)-2-oxoethyl) pyridinium] hydrazine dichloride. (compound no: 40), Yield 37% M.P Above 166-168°c(dec) IR (KBr,cm -1 ) 1666,1500 1 HNMR (DMSO d 6 , 400 MHz) δ 11.73(2H,s) , 9.59(2H,s) , 9.19-9.15(4H,d) 8.45-8.42(2H,t), 8..06-8.05(2H,d) ,7.15-7.14(2H,d), 6.43 (4H,s), 2.59(6H,s) Mass(m/z) 519,520,521,522 Example 42 N-N'-Bis[3-carbonyl-1-(2-(2-ethoxycarbenyl pyrrolidin-1-yl)-2-oxoethyl) pyridinium] hydrazine dichloride. (compound no: 41), Yield 28% M.P 118-120°c IR (KBr,cm -1 ) 1660,1510 1 HNMR (DMSO d 6 , 400 MHz) δ 11.75(2H,s) , 9.51(2H,s), 9.20-9.10(4H,m) 8.43-8.40(2H,t), 5.97-5.83(4H,m) ,4.39-4.36(2H,m), 4.27-4.22(1H,q), 4.12-4.05(4H,m), 3.71-3.63(4H,m), 3.48-3.40(1H,m), 2.26-2.19(2H,m), 2.05-1.91(5H,m) , 1.30-1.27(1H,t), 1.19-1.15(5H,t) Mass(m/z) 609,610,611 Example 43 1-[1-(2-Thien-2'-yl-2-oxoethyl)-5-aminocarbonyl-3-carbonyl pyridinium]-2-[1-(2-Thien-2'-yl-2-oxoethyl)-3-carbonyl pyridinium] hydrazine dichloride (compound no: 42), Yield 54% M.P Above 127-129°c(dec) IR (KBr,cm -1 ) 1678,1513 1 HNMR (DMSO d 6 , 400 MHz) δ 11.86(2H,s) , 9.83-9.64(4H,t) , 9.24 -9.23(2H,s) 8.82(1H,s), 8.48-8.45(1H,t), 8.34(1H,s) 8.26-8.24(4H,m), 7.44 -7.42(2H,d), 6.52-6.46(4H,d) Mass (m/z) 534,535,536 Example 44 1-(2-(4-carbethoxy-thiazolidin-3yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride (compound no: 43), Yield 29% M P 190-192°c IR (KBr,cm -1 ) 1673,1541 1 HNMR (DMSO d 6 , 400 MHz) δ 11.50(1H,s) , 9.55(1H,s) , 9.48(1H,s) , 9.12-9.08(2H,m) , 8.39-8.34(1H,t), 6.04 - 5.99(2H,m) , 4.94 -4.91(1H,m) , 4.87-4.84(1H,d), 4.73-4.71(1H,d), 4.28-4.23(1H,q), 4.14 -4.09(1H,q), 3.43-3.38(1H,m),3.27-3.22(1H,m), 3.10(3H,s) ,1.30-1.27(1H,t), 1.20-1.17(2H,m) Mass(m/z) 439,440,441 Example 45 N-N'-Bis[3-carbonyl-1-(2-(5-chloro-thien-2-yl)-2-oxoethyl) pyridinium] hydrazine dichloride. (compound no: 44), Yield 35% M.P Above 200-205°c (dec) IR (KBr,cm -1 ) 1674,1590,1500 1 HNMR (DMSO d 6 , 400 MHz) δ 11.90(2H,s), 9.64 -9.61(2H,d), 9.29-9.20(4H,m), 8.47-8.44(2H,t), 8.18-8.17(2H,d),7.51-7.50(2H,d), 6.49-6.48(4H,s) Mass(m/z) 559,560,561,562,563,564 Example 46 1-(2-(5-Methyl-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride (compound no: 45), Yield 22% M.P 196-198°c IR (KBr,cm -1 ) 1689,1657 1 HNMR (DMSO d 6 , 400 MHz) δ 11.47(1H,s) ,9.98(1H,s) ,9.53(1H,s) ,9.17-9.16(1H,d) , 9.09-9.07(1H,d) , 8.42-8.38(1H,t), 8.06-8.05(1H,d) , 7.15-7.14(1H,d), 6.41(2H,s), 3.09(3H,s), 2.59(3H,s) Mass(m/z) 354,355,356,357 Example 47 1-(2-(4-Nitro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium bromide. (compound no: 46), Yield 52% M.P Above 200-205°c(dec) IR (KBr,cm -1 ) 1688,1631,1541 1 HNMR (DMSO d 6 , 400 MHz) δ 11.41(1H,s) , 9.50(1H,s) 9.309-9.306(1H,d), 9.17-9.15(1H,d) ,9.09-9.07(1H,d) , 8.866-8.862(1H,d) ,8.45-8.41(1H,t) , 6.50(2H,s), 3.09(3H,s) Mass(m/z) 385,386,387 Example 48 1-(2-Phenylamino-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium chloride (compound no: 47), Yield 45% M.P 165-167°c IR (KBr,cm -1 ) 1679,1626,1600,1497 1 HNMR (DMSO d 6 , 400 MHz) δ 11.18(1H,s) , 11.10(1H,s) , 9.62(1H,s) , 9.24-9.22(1H,d) , 9.17-9.15(1H,d), 8.40-8.36(1H,t) , 8.19(1H,s), 7.63-7.61(2H,d) , 7.37-7.33(2H,t) , 7.20-7.16(2H,t), 7.12-7.09(1H,t) , 6.88-6.86(2H,d), 6.78-6.74(1H,t) , 5.78(2H,s) Mass(m/z) 347,348,349 Example 49 1-(2-Phenylamino-2-oxoethyl)-4 -[2-(benzoyloxy) ethylamino carbonyl] pyridinium chloride (compound no: 48), Yield 40% M.P 178-180°c IR (KBr,cm -1 ) 1700,1666,1559 1 HNMR (DMSO d 6 , 400 MHz) δ 11.13(1H,s) , 9.74 -9.71(1H,t) , 9.23-9.22(2H,d) , 8.52-8.50(2H,d) , 8.01-7.99(2H,d) , 7.68-7.60(3H,m) , 7.54-7.51(2H,t) , 7.36-7.32(2H,t) , 7.12-7.08 (1H,t) , 5.75 (2H,s) , 4.47-4.45(2H,t) , 3.77-3.72(2Hq). Mass (m/z) 404,405,406 Example 50 1-2-(5-Nitro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride (compound no: 49), Yield 10% M.P Above 105-110°c(dec) IR (KBr,cm -1 ) 1680,1620 1 HNMR (DMSO d 6 , 400 MHz) δ 11.48(1H,s), 9.98(1H,s), 9.52(1H,s) , 9.16-9.10(2H,m) ,8.45-8.41(1H,t) , 8.35-8.34(1H,d) ,8.25-8.24(1H,d) , 6.50(2H,s), 3.09(3H,s). Mass (m/z) 385,386,387 Example 51 1-(2-Thien-2'-yl-2-oxoethyl)3-(Trifluromethanesulfonyl hydrazino carbonyl)-pyridinium bromide (compound no: 50), Yield 22% M.P 77-79°c IR (KBr,cm -1 ) 2960, 1690, 1673, 1591 1 HNMR (DMSO d 6 , 400 MHz) δ 11.76(1H,s) , 11.27(1H,s), 9.61(1H,s) , 9.20-9.19(1H,d) ,9.07-9.05(1H,d) , 8.44-8.41(1H,t) ,8.25-8.22(2H,m) , 7.34 - 7.41 (1H,m), 6.46 (2H,s). Mass (m/z) 394, 395, 396 Example 52 1-(2-Thien-2'-yl-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium bromide (compound no. 51), Yield 10% M.P 192-194°c IR (KBr,cm -1 ) 1669,1663,1603, 1 HNMR (DMSO d 6 , 400 MHz) δ 10.99(1H,s) , 9.54(1H,s) , 9.17-9.14(2H,t), 8.44-8.41(1H,t) , 8.25-8.22(3H,m), 7.43-7.41(1H,t) , 7.20-7.16(2H,t), 6.87-6.85(2H,d) , 6.79-6.75(1H,t) , 6.46(2H,s) Mass(m/z) 338,339,340 Example 53 1-(2-Thien-2'-yl-2-oxoethyl)-3-(p-methoxy phenyl sulfonyl hydrazino carbonyl) pyridinium bromide (compound no. 52), Yield 28% M.P 126-128°c IR (KBr,cm -1 ) 1672,1653,1596 1 HNMR (DMSO d 6 , 400 MHz) δ 11.34 -11.33(1H,d), 10.27-10.26(1H,d), 9.34(1H,s), 9.13-9.12(1H,d) , 8.94-8.92(1H,d), 8.38-8.34(1H,t) ,8.24-8.19(2H,m),7.82-7.75(2H,m) ,7.42-7.40(1H,t), 7.07-7.04(2H,d) ,6.40(2H,s), 3.81(3H,s). Mass(m/z) 432,433,434 Example 54 1-(2-Ethoxy-2-oxoethyl)-3-(phenyl aminocarbonyl hydrazino carbonyl) pyridinium bromide. (compound no. 53), Yield 25% M.P 183-185°c IR (KBr,cm -1 ) 1746,1717,1682 1 HNMR (DMSO d 6 , 400 MHz) δ 11.02(1H,s) , 9.57(1H,s) , 9.22-9.21(1H,d), 9.11-9.09(1H,d) , 9.00(1H,s), 8.57(1H,s) ,8.44-8.41(1H,m),7.47-7.45(2H,d) ,7.29-7.25(2H,t) , 7.00-6.96(1H,t), 5.74(2H,s), 4.28-4.23(2H,q), 1.28-1.25(3H,t). Mass(m/z) 343,344,345,346 Example 55 1-(2-Ethoxy-2-oxoethyl)-3-(p-toluene sulfonyl hydrazino carbonyl) pyridinium bromide. (compound no. 54), Yield 54% M.P 174-176°c IR (KBr,cm -1 ) 1746,1712,1634 1 HNMR (DMSO d 6 , 400 MHz) δ 11.33(1H,s) , 10.36(1H,s) , 9.37(1H,s) , 9.18-9.16(1H,d) , 8.93-8.91(1H,d) , 8.37-8.33(1H,t) , 7.78-7.76(2H,d) , 7.37-7.35(2H,d) , 5.68 (2H,s) , 4.26-4.20(2H,q) ,2.37(3H,s),1.27-1.23(3H,t). Mass (m/z) 378,379,380,381 Example 56 1-(2-Phenyl-2-oxoethyl)-3-(phenylamino carbonyl hydrazino carbonyl) pyridinium bromide. (compound no. 55), Yield 70% M.P 206-208°c IR (KBr,cm -1 ) 1713,1684,1634 1 HNMR (DMSO d 6 400 MHz) δ 11.05(1H,s), 9.55(1H,s) , 9.18-9.13(2H,m) , 9.02(1H,s) , 8.59(1H,s) , 8.49-8.45(1H,m) ,8.09-8.07(2H,d), 7.84-7.80(1H,t), 7.71-7.67(2H,t) , 7.49-7.47(2H,d), 7.30-7.26(2H,t) , 7.01-6.97 (1H,t) ,6.56(2H,s) . Mass (m/z) 375,376,377 Example 57 1-(2-Phenylamino-2-oxoethyl)-3-(benzyl sulfonyl hydrazino carbonyl) pyridiniumchloride. (compound no. 56), Yield 48% M.P 208-210°c IR (KBr,cm -1 ) 1712,1681,1632 1 HNMR (DMSO d 6 , 400 MHz) δ 11.46(1H,s),10.80(1H,s) , 9.59(1H,s), 9.22-9.20(1H,d) ,9.08-9.06(1H,d), 8.38-8.36(1H,t),7.60-7.58(2H,d) ,7.49(2H,m) , 7.39-7.34(5H,m),7.13-7.10(1H,t), 5.74(2H,s), 4.52(2H,s),. Mass(m/z) 425,426,427,428 Example 58 1-(2-Phenyl-2-oxoethyl)-4-(methanesulfonyl hydrazino carbonyl) pyridinium bromide (compound no. 57), Yield 10% M.P 190-192°c IR (KBr,cm -1 ) 1679,1630,1650 1 HNMR (DMSO d 6 , 400 MHz) δ 11.54(1H,s) , 10.03(1H,s), 9.20-9.18(2H,d), 8.59-8.57(2H,d), 8.10-8.08(2H,d) , 7.84 -7.80(1H,t), 7.71-7.67(2H,t) , 6.56(2H,s) , 3.08(3H,s). Mass(m/z) 334,335,336 Example 59 1-(2-Phenyl-2-oxoethyl)-3-(phenyl hudrazino carbonyl) pyridinium bromide (compound no. 58), Yield 36% M.P 204-206°c IR (KBr,cm -1 ) 1686,1653,1630 1 HNMR (DMSO d 6 , 400 MHz) δ 11.01(1H,s) ,9.53(1H,s) ,9.17-9.16(2H,m) , 8.46-8.42(1H,t) , 8.09-8.07(2H,d) , 7.82-7.78(1H,t), 7.69-7.65(2H,t), 7.20-7.16(2H,t), 6.88-6.86(2H,d), 6.79-6.75(1H,t), 6.56(2H,s) Mass(m/z) 332,333 Example 60 1-(2-Ethoxy-2-oxoethyl)-4-[2-(benzoyloxy) ethyl amino carbonyl] pyridinium bromide (compound no. 59), Yield 82% M.P 154-156°c IR (KBr,cm -1 ) 1742,1719,1707,1675 1 HNMR (DMSO d 6 , 400 MHz) δ 9.57-9.54(1H,t), 9.22-9.20(2H,d) , 8.51-8.49(2H,d), 8.00-7.98(2H,d), 7.68-7.64(1H,t), 7.54 -7.51(2H,t), 5.72(2H,s), 4.47-4.44(2H,t) , 4.27-4.21 (2H,q) , 3.76-3.72(2H,q), 1.27-1.24. (3H,t) Mass(m/z) 357,358,359. Example 61 1-(2-Ethoxy-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium bromide.(compound no. 60), Yield 37% M.P 185-187°c IR (KBr,cm -1 ) 1740,1690,1630. 1 HNMR (DMSO d 6 , 400 MHz) δ 11.01(1H,s) , 9.58(1H,s) , 9.23-9.14(2H,m), 8.42-8.39(1H,t), 8.19(1H,s) , 7.20-7.16(2H,t), 6.87-6.85(2H,d), 6.78-6.75(1H,t) , 5.75(2H,s), 4.28-4.22(2H,q), 1.28-1.24(3H,t) Mass(m/z) 300,301,302. Example 62 1-(2-Phenyl-2-oxoethyl)-3-(p-methoxyphenyl sulfonyl hydrazino carbonyl) pyridinium bromide (compound no. 61), Yield 59% M.P 188-190°c IR (KBr,cm -1 ) 1671,1634,1580. 1 HNMR (DMSO d 6 , 400 MHz) δ 11.26-11.25(1H,d), 10.17- 10.16(1H,d), 9.24(1H,s), 9.03-9.01(1H,d), 8.87-8.85(1H,d), 8.31-8.27(1H,t), 7.97-7.96(2H,d), 7.74 -7.69(3H,m), 7.60-7.56(2H,t) , 6.99-6.97(2H,d) , 6.40(2H,s), 3.73(3H,s). Mass(m/z) 426,427,428,429 Example 63 1-(2-Phenyl-2-oxoethyl)- 4-[2-(benzoyloxy) ethyl amino carbonyl] pyridinium bromide (compound no. 62), Yield 92% M.P 202-204°c IR (KBr,cm -1 ) 1715,1692,1650 1 HNMR (DMSO d 6 , 400 MHz) δ 9.55(1H,s) , 9.14 -9.13(2H,d) , 8.52-8.51(2H,d), 8.07-7.99(4H,m) , 7.80-7.51(6H,m) , 6.52(2H,s), 4.46(2H,s), 3.76-3.75(2H,s). Mass(m/z) 3.89,390,391,392 Example 64 1-(2-Ethoxy-2-oxoethyl)- 4-(p-methanesulfonyl hydrazino carbonyl) pyridinium bromide. (compound no. 63), Yield 45% M.P 94-96°c IR (KBr,cm -1 ) 1726,1681,1643 1 HNMR (DMSO d 6 , 400 MHz) δ 11.49(1H,s) ,9.98(1H,s) ,9.23-9.21(2H,d), 8.54-8.52(2H,d) , 5.73(2H,s), 4.28-4.22(2H,q), 3.09(3H,s), 1.28-1.25(3H,t). Mass(m/z) 302,303,304,305. Pharmaceutical Compositions Pharmaceutical compositions may be prepared with a pharmaceutically effective quantity of compounds of general formula I, individually or in combination. The following pharmaceutical formulations suggested are by way of example alone and in no way restrict the forms in which they can be used. Oral formulations Oral formulations may be administered as solid dosage forms for example pellets, powders, sachets or discreet units such as tablets or capsules and like. Other orally administered pharmaceutical preparations include monophasic and biphasic liquid dosage forms either in ready to use form or forms suitable for reconstitution such as mixtures, syrups, suspensions or emulsions. The preparations in addition may contain diluents, dispersing agents, buffers, stabilizers, solubilizers, surfactants, preservatives, chelating agents and/ or other pharmaceutical additives as are used. Aqueous or non aqueous vehicle or their combination may be used and if desired may contain suitable sweetener, flavoring agent or similar substances. In case of suspension or emulsion a suitable thickening agent or suspending agent or emulsifying agent may be present in addition. Alternatively, the compounds may be administered as such in their pure form unassociated with other additives for example as capsules or sachets. It may also be administered with a vehicle. Pharmaceutical preparations can have a slow, delayed or controlled release of active ingredients as is provided by a matrix or diffusion controlled system. When the present invention or its salts or suitable complexes is presented as a discreet unit dosage form like tablet, it may contain in addition medically inert excipients as are used in the art. Diluents such as starch, lactose, dicalcium phosphate, talc, magnesium stearate, polymeric substances like methyl cellulose, fatty acids and derivatives, sodium starch glycollate, etc. may also be used. Example 65 Preparation of oral dosage form: A typical tablet has the following composition: Active ingredient of formula I as given above Lactose 135 mg Starch 76 mg Polyvinyl pyrolidone (K-30) 2 mg Talc 1.5 mg Magnesium Stearate 1.0 mg Parenteral Formulations For parenteral administration, the compounds or their salts or suitable complexes thereof may be present in a sterile vehicle which may be an aqueous or non aqueous vehicle or a combination thereof. The examples of vehicles are water, ethyl oleate, oils and derivatives of polyols, glycols and their derivatives. It may contain additives common in injectable preparations like stabilizers, solubilizers, pH modifiers, buffers, antioxidants, cosolvents, complexing agents, tonicity modifiers, etc. Some suitable additives are for example tartrate, citrate or similar buffers, alcohol, sodium chloride, dextrose and high molecular weight polymers. Another alternative is sterile powder reconstitution. The compound may be administered in the form of injection for more than once daily administration, or intravenous infusion/ drip or suitable depot preparation. Example 66 Preparation suitable for parenteral administration has the following composition: Active ingredient of formula I as given above Polyethylene glycol (400) 0.75 ml Sodium metabisulphite 0.01% Isotonic saline/ WFI q.s. Other Formulations. For the dermatological application and for the discoloration of teeth, the recommended formulations are lotions, oral rinse and toothpaste containing appropriate amount of the present specific compounds of the general formula I.

Claims: A pyridinium derivative which is selected from the group consisting of the following compounds: (a) N,N'bis [3-carbonyl-1-(2-thien-2'-yl-2-oxoethyl)pyridinium] hydrazine dichloride, (b) N,N'bis[3-carbonyl-1-(2-cyclopropylaminio-2-oxoethyl) pyridinium] hydrazine dichloride, (c) 1-(2-phenylamino-2-oxoethyl)-4-(phenylsulfonyl hydrazino carbonyl)pyridimum chloride and pharmaceutically acceptable salts thereof, (d) 1-(2-(2',4'-dichlorophenyl)-2-oxoethyl)-3- (2(methoxy) ethyloxycarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof, (e) 1-(2-phenylamino-2-oxoethyl)-3-((benzoyloxy) ethylaminocarbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof, (f) 1-(2-thien-2'-yl-2-oxoethyl)-3-(phenylaminocarbonyl hydrazinocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof, (g) 1-(2-phenyl-2-oxoethyl)-3-(2-(acetoxy) ethylaminocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof, (h) 1-(2-phenylamino-2-oxoethyl)-3-(phenyl sulfonyl hydrazino carbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof, (i) 1-(2-phenylamino-2-oxoethyl)-3-((4-methylphenyl)sulfonyl hydrazinocarbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof, (j) 1-(2-phenyl-2-oxoethyl)-3-(2-(benzoyloxy)ethyloxy carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof, (k) 1-(2-thien-2'-yl-2-oxoethyl)-3-(phenylcarbonyl hydrazino carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof, (l) 1-(2-ethoxy-2-oxoethyl)-3-((phenylmethyl)sulfonyl hydrazino carbonyl)pyridinium bromide and pharmaceutically acceptable salts thereof, (m) 1-(2-phenyl-2-oxoethyl)-3-((phenylmethyl)sulfonyl hydrazino carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof, (n) N,N' bis [3-carbonyl-1-(2-furan-2'-yl-2-oxoethyl)pyridinium] hydrazine dibromide, (o) 1-(2',4'-dichloro-phenyl-2-oxoethyl)-3-(2-methoxy ethyl aminocarbonyl)-pyridinium bromide, (p) 1-(2-thien-2'-yl-2-oxoethyl)-3-((2-methoxy ethyl) amino carbonyl)-5-bromo pyridinium chloride, (q) 1-(2-thien-2'-yl-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride, (r) 1-(2-thien-2'-yl-2-oxoethyl)-3-(2-(2-chloro-3-pyridoylhydrazinocarbonyl)-pyridinium chloride, (s) 1-(2-cyclopropylamino-2-oxoedtyl)-3-(2-memoxyethylaminocarbonyl)-pyridinium chloride, (t) 1-(2-isopnopylamino-2-oxoethyl)-3-(2-methylsulfonylhydrazinocarbonyl)-pyridinium chloride, (u) 1-(2-phenylamino-2-oxoethyl)-3-((2-(1-oxo-3-cyclohexyl)-propyl) hydrazino-carbonyl)-pyridinium bromide, (v) 1-(2-thien-2'-yl-2-oxoethyl)-3-[2-(benzoyloxy)ethylamino carbonyl]-pyridinium bromide, (w) 1-(4-ethoxy-2,4-dioxobutyl)-3-(2-(benzoxyloxy)ethylamino carbonyl)-pyridinium chloride, (x) 1-(2-thien-2'-yl-2-oxoethyl)-3-[1-oxo-1 -(2-methoxy carbonyl) pyridyl] hydrazino pyridinium chloride, (y) 1-[1-(2-thien-2'-yl-2-oxoethyl)-5-aminocarbonyl-3-carbonyl pyridinium]-2-[1-(2-thien-2'-yl-2-oxoethyl)-3-carbonyl pyridinium] hydrazine dichloride, (z) 1-(2-thien-2'-yl-2-oxoethyl)-3-(trifluoromethanesulfonyl hydrazino carbonyl) - pyridinium bromide, (aa)1-[1-(2-thien-2'-yl-2-oxoethyl)-6-methyl-3-carbonylpyridinium]-2-[1-(2-thien-2'-yl-2-oxoethyl)-3-carbonyl pyridinium] hydrazine dichloride, (ab) N,N'-bis[3-carbonyl-1-(2-(5-methyl-thien-2-yl)-2-oxoethyl) pyridinium] hydrazine dichloride, (ac) N,N'-bis[3-carbonyl-1-(2-(5-chloro-thien-2-yl)-2-oxoethyl) pyridinium] hydrazine dichloride, (ad) 1-(2-thien-2'-yl-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl)-6-methyl pyridinium bromide, (ae) N,N'-bis[3-carbonyl-1 -(2-(4-nitro-thien-2-yl)-2-oxoethyl) pyridinium] hydrazine dichloride, (af) 1-(2-phenylamino-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium chloride, (ag) 1-(2-(4-nitro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium bromide, (ah) 1-(2-(5-nitro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride, (ai) 1-(2-(5-chloro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium bromide, (aj) 1-(2-thien-2'-yl-2-oxoethyl)-3-(ethoxycarbonyl hydrazino carbonyl) pyridmium bromide, (ak) 1-(2-thien-2'-yl-2-oxoethyl)-3-(isopropylsulfonyl hydrazino carbonyl) pyridinium bromide, (al) 1-(2-thien-2'-yl-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl)-5-bromo pyridinium bromide, (am) 1-(2-(2-ethoxy carbonyl pyrrolidin-1-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride, (an) 1-(2-(5-methyl-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride, (ao) 1-(2-(4-carbethoxy-thiazolidin-3-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride, (ap) 1-(2-(4-benzylpiperidin-1-yl)-2-oxoethyl)-3-(medmesulfonyl hydrazino carbonyl) pyridinium chloride, (aq) N,N'-bis[3-carbonyl-1-(2-(2-ethoxycarbonyl pyrrolidin-1-yl)-2-oxoethyl) pyridinium] hydrazine dichloride, (ar) 1-(2-phenylamino-2-oxoethyl)-4-[2-(benzoyloxy) ethylamino carbonyl] pyridinium chloride, (as) 1-(2-thien-2'-yl-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium bromide, (at) 1-(2-thien-2'-yl-2-oxoethyl)-3-(p-methoxy phenyl sulfonyl hydrazino carbonyl) pyridinium bromide, (au) 1-(2-ethoxy-2-oxoethyl)-3-(phenyl aminocarbonyl hydrazino carbonyl) pyridinium bromide, (av) 1-(2-ethoxy-2-oxoethyl)-3-(p-toluene sulfonyl hydrazino carbonyl) pyridinium bromide, (aw) 1-(2-phenyl-2-oxoethyl)-3-(phenylamino carbonyl hydrazino carbonyl) pyridinium bromide, (ax) 1-(2-phenylamino-2-oxoethyl)-3-(benzyl sulfonyl hydrazino carbonyl) pyridiniumchloride, (ay) 1-(2-phenyl-2-oxoethyl)-4-(methanesulfonyl hydrazino carbonyl) pyridinium bromide, (az) 1-(2-phenyl-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium bromide, (ba) 1-(2-ethoxy-2-oxoethyl)-4-[2-(benzoyloxy) ethyl amino carbonyl] pyridinium bromide, (bb) 1-(2-ethoxy-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium bromide, (be) 1-(2-phenyl-2-oxoethyl)-3-(p-methoxyphenyl sulfonyl hydrazino carbonyl) pyridinium bromide, (bd) 1-(2-phenyl-2-oxoethyl)- 4-[2-(benzoyloxy) ethyl amino carbonyl] pyridinium bromide and (be) 1-(2-ethoxy-2-oxoethyl)- 4-(p-methanesulfonyl hydrazino carbonyl) pyridinium bromide. A process for the preparation of compounds as claimed in claim 1, which comprises i) refluxing a pyridine derivative selected from : (a) N,N'-bis(nicotinyl)hydrazine (b) 3-[(2-pyridyl)hydrazinocarbonyl]pyridine (c) 3-[(2-methanesulfonyl)hydrazinocarbonyl]pyridine (d) 3-[(2-benzoyloxy)ethylaminocarbonyl]pyridine (e) 3-[(2-phenylsulfonyl)hydrazinocarbonyl]pyridine (f) 3-[(2-acetoxy)ethyloxycarbonyl]pyridine (g) 3-[(2-benzoyloxy)ethyloxycarbonyl]pyridine (h) 3-[(2-methoxy)ethyloxycarbonyl]pyridine (i) 3-[(2-phenylaminocarbonyl)hydrazinocarbonyl]pyridine (j) 3-[(2-acetoxy)ethylaminocarbonyl]pyridine (k) 3-[(2-(4-methylphenyl sulfonyl)hydrazinocarbonyl]pyridine (l) 3-[(2-benzoyl)- hydrazinocarbonyl]pyridine (m) 3-[(2-phenylmethanesulfonyl) hydrazinocarbonyl] pyridine (n) 3-[(2-(3-cyclohexylpropanoyl)hydrazinocarbonyl]pyridine (o) 3-[(2-methoxy) ethylaminocarbonyl]pyridine (p) 3-[1-oxo-1-(2-methoxycarbonyl)pyridyl]hydrazino pyridine with a quaternizing agent selected from the group comprising of : (a) 2-bromoacetyl thiophene (b) 2-chloroacetyl thiophene (c) phenacylbromide (d) phenacylchloride (e) 2,4-dichlorophenacylbromide (f) N-phenyl chloroacetamide (g) N-cyclopropyl chloroacetamide (h) Ethylbromoacetate (i) Bromo acetylfuran (j) N-isopropylchloroacetamide (k) N-chloroacetyl-2-pyrrolidinone and (l) chloroacetic acid in an alcoholic solvent selected from the group comprising of: (a) methanol (b) ethanol (c) n-propanol and (d) isopropanol and / or a high boiling solvent selected from the group comprising of: (a) toluene (b) o-xylene (c) m-xylene (d) p-xylene and (e) xylenes for 6-48 hours. (ii) isolating the compound from step (i). The use of compound as claimed in claim 1, in the manufacture of a medicament for diabetic complications and aging-related diseases, including kidney disease, nerve damage, retinopathy, atherosclerosis, microangiopathy, endothelial dysfunctions, dermatological conditions, discoloration of teeth and other organ dysfunctions. A pharmaceutical composition for treatment of diabetic complications and aging related diseases which comprises a pharmaceutically effective amount of one or more compounds as claimed in claim 1, or pharmaceutically acceptable salt(s) thereof in admixture with a pharmaceutically acceptable carrier, diluent, solvent or excepient. The pharmaceutical composition as claimed in claim 4, in the form of an oral formulation. The pharmaceutical composition as claimed in claim 5, wherein said pharmaceutically acceptable carrier is selected from group consisting of starch, lactose, polyvinyl pyrolidone (K-30), talc and magnesium stearate. The pharmaceutical composition as claimed in claim 4 in the form of a parenteral formulation. A method for the preparation of a parenteral formulation as claimed in claim 7, which comprises dissolving one or more compounds as defined in claim 1, in polyethylene glycol 400 and diluting the solution so obtained, with an isotonic solution or water to a desired concentration. Pharmaceutical composition as claimed in claim 6, in the form of a lotion, oral rinse and toothpaste. Use of the compound of claim 1 for the manufacture of a medicament for treating a diabetic patient by breaking a preformed AGE, within said patient, which comprises, administering an effective amount of said compound, either singly, or in combination with other drugs for antidiabetic therapy. Use of the compound of claim 1 for the manufacture of a medicament for preventing or treating diseases caused by diabetes and aging related complications, which comprises, administering to a patient in need thereof, an effective amount of said compound, either singly or in combination with a pharmaceutically acceptable carrier, diluent or excepient. The use as claimed in claim 11, wherein the diseaseprevented or treated is a nephrological disorder, neurological disorder, atherosclerosis, retinal disorder, dermatological disorder, non-enzymatic browning of oral cavity, endothelial or other organ dysfunction and growth impairment. The use of claim 12, wherein said compound is selected from the group consisting of: (a) N,N'bis [3-carbonyl-1-(2-thien-2'-yl-2-oxoethyl)pyridinium] hydrazine dichloride, (b) N,N'-bis-[3-carbonyl-1-(2-cyclopropylamino-2-oxoethyl) pyridinium] hydrazine dichloride, (c) 1-(2-phenylamino-2-oxoethyl)-4-(phenylsulfonyl hydrazino carbonyl)pyridinium chloride and pharmaceutically acceptable salts thereof, (d) 1-(2-(2',4'-dichlorophenyl)-2-oxoethyl)-3-(2(methoxy) ethyloxycarbonyl) pyridinium bromide and phannaceutically acceptable salts thereof, (e) 1-(2-phenylamino-2-oxoethyl)-3-((benzoyloxy) ethylaminocarbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof, (f) 1-(2-thien-2'-yl-2-oxoethyl)-3-(phenylaminocarbonyl hydrazinocarbonyl)pyridinium bromide and pharmaceutically acceptable salts thereof, (g) 1-(2-phenyl-2-oxoethyl)-3-(2-(acetoxy) ethylaminocarbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof, (h) 1-(2-phenylamino-2-oxoethyl)-3-(phenyl sulfonyl hydrazino carbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof, (i) 1-(2-phenylamino-2-oxoethyl)-3-((4-methylphenyl) sulfonyl hydrazinocarbonyl) pyridinium chloride and pharmaceutically acceptable salts thereof, (j) 1-(2-phenyl-2-oxoethyl)-3-(2-(benzoyloxy)ethyloxy carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof, (k) 1-(2-thien-2'-yl-2-oxoethyl)-3-(phenylcarbonyl hydrazino carbonyl) pyridinium bromide and pharmaceutically acceptable salts thereof, (l) 1-(2-ethoxy-2-oxoethyl)-3-((phenylmethyl)sulfonyl hydrazino carbonyl)pyridinium bromide and pharmaceutically acceptable salts thereof, (m) 1-(2-phenyl-2-oxoethyl)-3-((phenylmethyl)sulfonyl hydrazino carbonyl)pyridinium bromide and pharmaceutically acceptable salts thereof, (n) N,N-bis[3-carbonyl-1-(2-furan-2'-yl-2-oxoethyl) pyridinium] hydrazine dibromide, (o) 1-(2',4'-dichloro-phenyl-2-oxoethyl)-3-(2-methoxyethyl aminocarbonyl)-pyridinium bromide, (p) 1-(2-thien-2'-yl-2-oxoethyl)-3-((2-methoxy ethyl) amino carbonyl)-5-bromo pyridinium chloride, (q) 1-(2-thien-2'-yl-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride, (r) 1-(2-thien-2'-yl-2-oxoethyl)-3-(2-(2-chloro-3-pyridoylhydrazinocarbonyl)-pyridinium chloride, (s) 1-(2-cyclopropylamino-2-oxoethyl)-3-(2-methoxyethylaminocarbonyl)-pyridinium chloride, (t) 1-(2-isopropylamino-2-oxoethyl)-3-(2-methylsulfonylhydrazinocarbonyl)-pyridinium chloride, (u) 1-(2-phenylamino-2-oxo ethyl)-3-({2-(1-oxo-3-cyclohexyl)-propyl} -hydrazino-carbonyl)-pyridinium bromide, (v) 1-(2-thien-2'-yl-2-oxoethyl)-3-[2-(benzoyloxy)ethylamino carbonyl]-pyridinium bromide, (w) 1-(4-ethoxy-2, 4-dioxobutyl)-3-(2-(benzoxyloxy)ethylamino carbonyl)-pyridinium chloride, (x) 1-(2-thien-2'-yl-2-oxoethyl)-3 -[1-oxo-1-(2-methoxy carbonyl) pyridyl] hydrazino pyridinium chloride, (y) 1-[1-(2-thien-2'-yl-2-oxoethyl)-5-aminocarbonyl-3-carbonyl pyridinium]-2-[1-(2-thien-2'-yl-2-oxoethyl)-3-carbonyl pyridinium] hydrazine dichloride, (z) 1-(2-thien-2'-yl-2-oxoethyl)-3-(trifluoromethanesulfonyl hydrazino carbonyl) - pyridinium bromide, (aa) 1-[1-(2-thien-2'-yl-2-oxoethyl)-6-methyl-3-carbonylpyridinium]-2-[1-(2-thien-2'-yl-2-oxoethyl)-3-carbonyl pyridinium]hydrazine dichloride, (ab) N,N'-bis[3-carbonyl-1-(2-(5-methyl-thien-2-yl)-2-oxoethyl) pyridinium] hydrazine dichloride, (ac) N,N'-bis[3-carbonyl-1-(2-(5-chloro-thien-2-yl)-2-oxoethyl) pyridinium] hydrazine dichloride, (ad) 1-(2-tm'en-2'-yl-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl)-6-methyl pyridinium bromide, (ae) N,N'-bis[3-carbonyl-1 -(2-(4-nitro-thien-2-yl)-2-oxoethyl)pyridinium] hydrazine dichloride, (at) 1-(2-phenylamino-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium chloride, (ag) 1-(2-(4-nitro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium bromide, (ah) 1-(2-(5-nitro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride, (ai) 1-(2-(5-chloro-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium bromide, (aj) 1-(2-thien-2'-yl-2-oxoethyl)-3-(ethoxycarbonyl hydrazino carbonyl) pyridinium bromide, (ak) 1-(2-thien-2'-yl-2-oxoethyl)-3-(isopropylsulfonyl hydrazino carbonyl) pyridinium bromide, (al) 1-(2-thien-2'-yl-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl)-5-bromo pyridinium bromide, (am) 1-(2-(2-ethoxy carbonyl pyrrolidin-1-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride, (an) 1-(2-(5-methyl-thien-2-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride, (ao) 1-(2-(4-carbethoxy-thiazolidin-3-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride, (ap) 1-(2-(4-benzyl piperidin-1-yl)-2-oxoethyl)-3-(methanesulfonyl hydrazino carbonyl) pyridinium chloride, (aq) N,N'-bis[3-carbonyl-1-(2-(2-ethoxycarbonyl pyrrolidin-1-yl)-2-oxoethyl) pyridinium] hydrazine dichloride, (ar) 1-(2-phenylamino-2-oxoethyl)-4-[2-(benzoyloxy) ethylamino carbonyl] pyridinium chloride, (as) 1-(2-thien-2'-yl-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium bromide, (at) 1-(2-thien-2'-yl-2-oxoethyl)-3-(p-methoxy phenyl sulfonyl hydrazino carbonyl) pyridinium bromide, (au) 1-(2-ethoxy-2-oxoethyl)-3-(phenylaminocarbonyl hydrazino carbonyl) pyridinium bromide, (av) 1-(2-ethoxy-2-oxoethyl)-3-(p-toluene sulfonyl hydrazino carbonyl) pyridinium bromide, (aw) 1-(2-phenyl-2-oxoethyl)-3-(phenylamino carbonyl hydrazino carbonyl) pyridinium bromide, (ax) 1-(2-phenylamino-2-oxoethyl)-3-(benzyl sulfonyl hydrazino carbonyl) pyridinium chloride, (ay) 1-(2-phenyl-2-oxoethyl)-4-(methanesulfonyl hydrazino carbonyl) pyridinium bromide, (az) 1-(2-phenyl-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium bromide, - (ba) 1-(2-ethoxy-2-oxoethyl)-4-[2-(benzoyloxy)ethylamino carbonyl] pyridinium bromide, (bb) 1-(2-ethoxy-2-oxoethyl)-3-(phenyl hydrazino carbonyl) pyridinium bromide, (be) 1-(2-phenyl-2-oxoethyl)-3-(p-methoxyphenyl sulfonyl hydrazino carbonyl) pyridinium bromide, (bd) 1-(2-phenyl-2-oxoethyl)- 4-[2-(benzoyloxy) ethyl amino carbonyl] pyridinium bromide and (be) 1-(2-ethoxy-2-oxoethyl)- 4-(p-methanesulfonyl hydrazino carbonyl) pyridinium bromide.

Inventors: SANKARANARAYANAN ALANGUDI, SANKARANARAYANAN, ALANGUDI
Applicants: TORRENT PHARMACEUTICALS LTD
Application year: 2001
Main classification: C07D213
IPC codes: C07D409, A61K31, A61P25, A61P5, A61K8, A61P13, A61P3, A61Q11, A61K9, A61P43, C07D213, C07D417, A61Q19, C07D401, A61K47, C07D405, A61P9, A61P17